Abstract
Background: This study systematically evaluates the association between interleukin-6 (IL-6) gene polymorphisms and osteoarthritis (OA) risk through a meta-analysis.
Methods: Following PRISMA guidelines, a literature search was conducted in several databases, including studies published up to February 2025. Eligible studies included OA patients diagnosed by ACR criteria, investigating IL-6 gene promoter polymorphisms (rs1800795, rs1800797, rs1800798) and reporting genotype data or odds ratios (ORs) with 95% confidence intervals (CIs). Meta-analysis was performed using Stata 15.1, and subgroup analyses (ethnicity, OA subtype), and Egger's test were conducted.
Results: A total of 13 case-control studies (16 datasets) were included, covering three major IL-6 gene polymorphic sites: The 174 G/C (rs1800795) polymorphism showed no significant association with OA risk in overall or subgroup analyses (P > 0.05). The 572 G/C (rs1800797) polymorphism was significantly associated with a reduced OA risk under the dominant model (OR = 0.68, 95% CI: 0.48–0.97, P < 0.05), particularly demonstrating a protective effect in KOA. The 597 G/A (rs1800798) polymorphism showed no significant correlation with OA susceptibility (P > 0.05). Subgroup analyses confirmed result stability. Egger's test detected no significant publication bias.
Conclusion: IL-6 gene polymorphisms exhibit site- and population-specific effects on OA risk. The 572 G/C variant may confer protection against KOA. Further large-scale, multicenter studies are needed to validate these findings and explore underlying mechanisms for early OA diagnosis and personalized interventions.
Keywords
Gene polymorphism
Osteoarthritis
Knee joint
Meta-analysis
Genetic susceptibility
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.